Assays

Each assay in the OncoFirm™ pipeline runs on the same platform: our Proprietary Fluorescent Lateral Flow Antigen Technology, which delivers quantitative results in minutes from a small sample, read on a compact fluorescent reader. Our lead program is CEA for colorectal cancer monitoring, followed by PSA. Hepatitis B and C panels are in development. Infectious disease, inflammation and cardiac markers are planned next, with prenatal, viral and tropical disease assays further out. Every page below explains why the marker matters, how the test works and where it stands on our roadmap. We welcome clinical, research and commercial partners at every stage.

Assays | Rapid Test - Lateral Flow Tests

Hepatitis B Panel — HBsAg, Anti-HBs and Anti-HBc Fluorescent Assay

Hepatitis B fluorescent assay program: quantitative HBsAg first, with anti-HBs and anti-HBc planned, on the OncoFirm reader. In development; not for sale.

Read More Hepatitis B Panel — HBsAg, Anti-HBs and Anti-HBc Fluorescent Assay
Assays | Recombinant Antigens

Recombinant Cardiac Troponin I (cTnI) — Calibrator and Control Antigen

Recombinant cardiac troponin I (cTnI) antigen supporting OncoFirm’s quantitative troponin assay as calibrator and control material. Research use only.

Read More Recombinant Cardiac Troponin I (cTnI) — Calibrator and Control Antigen
Assays | Native Antigens

Alpha-1-Microglobulin (A1M) — Native Antigen and Future Kidney Marker

Native alpha-1-microglobulin (A1M) antigen for calibrators and controls, and a pipeline candidate for a quantitative urine kidney-function assay. Research use only.

Read More Alpha-1-Microglobulin (A1M) — Native Antigen and Future Kidney Marker
Assays | Rapid Test - Lateral Flow Tests

Cardiac Marker Panel — cTnI, CK-MB and Myoglobin Multiplex Assay

Planned OncoFirm cardiac multiplex panel: quantitative troponin I, CK-MB and myoglobin from one sample on a handheld reader. Not for sale.

Read More Cardiac Marker Panel — cTnI, CK-MB and Myoglobin Multiplex Assay
Assays | Rapid Test - Lateral Flow Tests

Cardiac Troponin I (cTnI) — Quantitative Fluorescent Assay

Planned OncoFirm quantitative cardiac troponin I (cTnI) fluorescent assay for serial point-of-care measurement. Not for sale.

Read More Cardiac Troponin I (cTnI) — Quantitative Fluorescent Assay
Assays | Rapid Test - Lateral Flow Tests

Myoglobin — Quantitative Fluorescent Assay

Planned myoglobin quantitative fluorescent assay as a supporting marker in OncoFirm’s cardiac panel alongside troponin I. Not for sale.

Read More Myoglobin — Quantitative Fluorescent Assay
Assays | Rapid Test - Lateral Flow Tests

AFP (Alpha-Fetoprotein) — Quantitative Fluorescent Assay

AFP (alpha-fetoprotein) quantitative fluorescent assay, a future pipeline candidate for OncoFirm’s cancer panel and liver cancer surveillance. Not for sale.

Read More AFP (Alpha-Fetoprotein) — Quantitative Fluorescent Assay
Assays | Rapid Test - Lateral Flow Tests

CEA (Carcinoembryonic Antigen) — Quantitative Fluorescent Assay

OncoFirm’s lead program: a quantitative fluorescent CEA assay (1–100 ng/mL design range) with a self-calibrating reference line and handheld reader. In development; not for sale.

Read More CEA (Carcinoembryonic Antigen) — Quantitative Fluorescent Assay
Assays | Rapid Test - Lateral Flow Tests

PSA (Prostate-Specific Antigen) — Quantitative Fluorescent Assay

Quantitative fluorescent PSA assay (0.5–50 ng/mL design range) on the same OncoFirm reader as CEA. Second cancer program, in development; not for sale.

Read More PSA (Prostate-Specific Antigen) — Quantitative Fluorescent Assay
Assays | Rapid Test - Lateral Flow Tests

Rubella IgG/IgM Antibody Assay

Future pipeline: rubella IgG/IgM antibody assay on the OncoFirm fluorescent reader for prenatal immunity checks. Not for sale.

Read More Rubella IgG/IgM Antibody Assay